TWI723028B - 化學化合物 - Google Patents
化學化合物 Download PDFInfo
- Publication number
- TWI723028B TWI723028B TW105120362A TW105120362A TWI723028B TW I723028 B TWI723028 B TW I723028B TW 105120362 A TW105120362 A TW 105120362A TW 105120362 A TW105120362 A TW 105120362A TW I723028 B TWI723028 B TW I723028B
- Authority
- TW
- Taiwan
- Prior art keywords
- pyridin
- chloro
- cyclohexanecarboxamide
- dihydro
- acetamido
- Prior art date
Links
- 0 CC1=C(*)N(*)N=I1 Chemical compound CC1=C(*)N(*)N=I1 0.000 description 6
- HYGVBDXATIOICV-OAHLLOKOSA-N CC(C)(C)OC(N(CCC1)C[C@@H]1C(Nc(cc1-c2cnc3[n]2CCCC3)ncc1Cl)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C[C@@H]1C(Nc(cc1-c2cnc3[n]2CCCC3)ncc1Cl)=O)=O HYGVBDXATIOICV-OAHLLOKOSA-N 0.000 description 1
- DVWKWCMDZWSNPV-VHSXEESVSA-N CC(C)(C)OC(N[C@H](CC1)C[C@H]1C(Nc(cc1I)ncc1Cl)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)C[C@H]1C(Nc(cc1I)ncc1Cl)=O)=O DVWKWCMDZWSNPV-VHSXEESVSA-N 0.000 description 1
- SMXYHNZGXDWVCU-JKSUJKDBSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3)[n]3nc2)ncc1Cl)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3)[n]3nc2)ncc1Cl)=O)=O SMXYHNZGXDWVCU-JKSUJKDBSA-N 0.000 description 1
- RSZWMUJXNNLRCA-WDEREUQCSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(I)c1F)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(I)c1F)=O)=O RSZWMUJXNNLRCA-WDEREUQCSA-N 0.000 description 1
- LZZMWGNQVKORNC-ZWKOTPCHSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CC(C)(C)C3)[n]3nc2)ccn1)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CC(C)(C)C3)[n]3nc2)ccn1)=O)=O LZZMWGNQVKORNC-ZWKOTPCHSA-N 0.000 description 1
- XEBCKCLAUDJKGC-RBUKOAKNSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CC(C)(C)CC3)[n]3nc2)ccn1)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CC(C)(C)CC3)[n]3nc2)ccn1)=O)=O XEBCKCLAUDJKGC-RBUKOAKNSA-N 0.000 description 1
- JZNYYYDHTLAEQE-UHFFFAOYSA-N CC(C)(C1)CN=C1SC Chemical compound CC(C)(C1)CN=C1SC JZNYYYDHTLAEQE-UHFFFAOYSA-N 0.000 description 1
- QVTYLIOVXVMVDH-UHFFFAOYSA-N CC(C)(C1)CNC1=S Chemical compound CC(C)(C1)CNC1=S QVTYLIOVXVMVDH-UHFFFAOYSA-N 0.000 description 1
- MGAVCFAPDCHXER-UHFFFAOYSA-N CC(C)(Cc1n[nH]cc1)CO Chemical compound CC(C)(Cc1n[nH]cc1)CO MGAVCFAPDCHXER-UHFFFAOYSA-N 0.000 description 1
- BRQSWVAJJNFGEP-IODPJOFQSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3O)[n]3nc2)ncc1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3O)[n]3nc2)ncc1Cl)=O)=O BRQSWVAJJNFGEP-IODPJOFQSA-N 0.000 description 1
- YDQRVRNJQTWKHE-QMRHZFGWSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCC(C3)OC)[n]3nc2)c1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCC(C3)OC)[n]3nc2)c1Cl)=O)=O YDQRVRNJQTWKHE-QMRHZFGWSA-N 0.000 description 1
- PAFCJOQZBCKRMU-PWUWZPNHSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCC(C3)OC)[n]3nc2)c1Cl)=O)O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCC(C3)OC)[n]3nc2)c1Cl)=O)O PAFCJOQZBCKRMU-PWUWZPNHSA-N 0.000 description 1
- FZFPAKGNEMHQAH-LSDHHAIUSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCCO)[nH]nc2)c1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCCO)[nH]nc2)c1Cl)=O)=O FZFPAKGNEMHQAH-LSDHHAIUSA-N 0.000 description 1
- BNKIFNPPAHGYBV-UHFFFAOYSA-N CC1(C)C[n]2ncc(-c(cc(N)nc3)c3F)c2C1 Chemical compound CC1(C)C[n]2ncc(-c(cc(N)nc3)c3F)c2C1 BNKIFNPPAHGYBV-UHFFFAOYSA-N 0.000 description 1
- ZZOHVSVTOBGPOG-JKSUJKDBSA-N CC1(C)C[n]2ncc(-c3c(C)cnc(NC([C@@H](CCC4)C[C@@H]4NC(CO)=O)=O)c3)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3c(C)cnc(NC([C@@H](CCC4)C[C@@H]4NC(CO)=O)=O)c3)c2C1 ZZOHVSVTOBGPOG-JKSUJKDBSA-N 0.000 description 1
- DVADGDLKHNVAJW-UHFFFAOYSA-N CC1(C)C[n]2ncc(-c3cc(N)ncc3Cl)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3cc(N)ncc3Cl)c2C1 DVADGDLKHNVAJW-UHFFFAOYSA-N 0.000 description 1
- YCAYESBFZMZNSE-BETUJISGSA-N CC1(C)C[n]2ncc(-c3ccnc(NC([C@H](C4)C[C@H]4O)=O)c3)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3ccnc(NC([C@H](C4)C[C@H]4O)=O)c3)c2C1 YCAYESBFZMZNSE-BETUJISGSA-N 0.000 description 1
- CXQVYRINUQQKCU-UHFFFAOYSA-N CC1(C)C[n]2ncc(I)c2C1 Chemical compound CC1(C)C[n]2ncc(I)c2C1 CXQVYRINUQQKCU-UHFFFAOYSA-N 0.000 description 1
- DEAHYRAFONDENL-UHFFFAOYSA-N CC1C[n]2ncc(I)c2CC1 Chemical compound CC1C[n]2ncc(I)c2CC1 DEAHYRAFONDENL-UHFFFAOYSA-N 0.000 description 1
- MDOJMKSZNORAKR-UHFFFAOYSA-N Cc(cnc(N)c1)c1I Chemical compound Cc(cnc(N)c1)c1I MDOJMKSZNORAKR-UHFFFAOYSA-N 0.000 description 1
- MEJZJBZKTCBDQI-LSDHHAIUSA-N OC1(CC1)C(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3)[n]3nc2)ncc1Cl)=O)=O Chemical compound OC1(CC1)C(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCC3)[n]3nc2)ncc1Cl)=O)=O MEJZJBZKTCBDQI-LSDHHAIUSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| US62/185,852 | 2015-06-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201718573A TW201718573A (zh) | 2017-06-01 |
| TWI723028B true TWI723028B (zh) | 2021-04-01 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105120362A TWI723028B (zh) | 2015-06-29 | 2016-06-28 | 化學化合物 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200289506A1 (en) | 2017-09-25 | 2020-09-17 | Astrazeneca Ab | Combination of a btk inhibitor and an inhibitor or cdk9 to treat cancer |
| WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2020259556A1 (zh) * | 2019-06-27 | 2020-12-30 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| CN114786673A (zh) * | 2019-09-11 | 2022-07-22 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
| EP4074699A4 (en) * | 2019-12-09 | 2024-01-03 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | COMPOUND USEFUL AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF |
| EP4140997A4 (en) | 2020-05-12 | 2023-09-06 | Suzhou Alphama Biotechnology Co., Ltd. | PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF |
| WO2021227904A1 (zh) | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| TW202216207A (zh) * | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及cdk9抑制劑之組合 |
| JP7537002B2 (ja) | 2020-08-07 | 2024-08-20 | 南京薬石科技股▲フン▼有限公司 | Ｃｄｋ９阻害剤およびその使用 |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247796A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| EP4452254A4 (en) * | 2021-12-23 | 2025-12-31 | The Katholieke Univ Leuven | TETRAHYDROPYRAZOLOPYRIMIDINES AND ASSOCIATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD |
| CN120051473A (zh) | 2022-08-17 | 2025-05-27 | 韩国化学研究院 | 抑制或降解cdk2和/或cdk9的化合物及其医学用途 |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| WO2024220876A1 (en) * | 2023-04-19 | 2024-10-24 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160017A1 (en) * | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| JP5693951B2 (ja) | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008132138A1 (en) * | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| HRP20110470T1 (hr) | 2007-10-12 | 2011-07-31 | Ingenium Pharmaceuticals Gmbh | Inhibitori proteinskih kinaza |
| BR112012008147A2 (pt) | 2009-09-04 | 2016-03-01 | Novartis Ag | compostos heteroarílicos como inibidores da quinase |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) * | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| NZ601924A (en) | 2010-03-10 | 2014-10-31 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| US20130303507A1 (en) * | 2011-01-28 | 2013-11-14 | Novartis Ag | Substituted hetero-biaryl compounds and their uses |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| EP2763993B1 (en) * | 2011-10-06 | 2017-04-19 | Bayer Intellectual Property GmbH | Heterocyclylpyri(mi)dinylpyrazole |
| MX2015012386A (es) | 2013-03-13 | 2016-02-03 | Abbvie Inc | Inhibidores de la cinasa cdk9. |
| WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| BR112015023078A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de pirrolopirimindina cdk9 quinase |
-
2016
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160017A1 (en) * | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI723028B (zh) | 化學化合物 | |
| TWI828358B (zh) | 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法 | |
| KR102388208B1 (ko) | 암을 치료하기 위한 거대 환형 mcl1 억제제 | |
| KR20220100879A (ko) | Fgfr 저해제로서의 이환식 헤테로사이클 | |
| TW201904976A (zh) | Ｍｃｌ-１抑制劑及其使用方法 | |
| TW201444820A (zh) | 吡啶ｃｄｋ９激酶抑制劑 | |
| TW202304907A (zh) | 溴域抑制劑 | |
| TW201900618A (zh) | 激酶抑制劑及其用途 | |
| CN105246890A (zh) | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 | |
| JP2021102619A (ja) | ブロモドメイン阻害剤 | |
| TW201103929A (en) | Heterocyclic urea derivatives and methods of use thereof | |
| HK40014442B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK40014442A (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK1250985B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK1250985A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| BR112017027394B1 (pt) | Composto, forma cristalina, composição farmacêutica e uso do mesmo | |
| CA3020378C (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| CN120265629A (zh) | 被取代的双环和三环hset抑制剂 |